Cell BioEngines, Inc

About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. Human body is made of ~37.2 trillion of functional cells and many incurable health problems occur due to irreversible damage to these cells. Our vision is to achieve a universal stem cell foundation platform where we can precisely generate any desired human cell state on demand and at scale, to repair or replace damaged tissue. The company utilizes a "plug-and-play" epigenetic regulatory platform to convert ‘non-gene modified’ donor blood stem cells into rare, potent clinical-grade cells for therapeutics, primarily oncology and regenerative medicine applications. Our strategy focuses on overcoming donor source availability, potency and scalability challenges to expand access to HLA-compatible cell therapies. Its lead product is currently in Phase 1 trials for the treatment of hematopoietic neoplasms not curable with available therapies. For more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines